Overview

XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2026-03-30

Target enrollment:

Participant gender:

Summary

This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of XTX101 as monotherapy and XTX101 and pembrolizumab combination therapy in patients with advanced solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Xilio Development, Inc.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab